210
Participants
Start Date
May 31, 2010
Primary Completion Date
December 31, 2010
Study Completion Date
February 3, 2011
BC-3781
BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
BC-3781
BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Vancomycin
Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
BC-3781 Study Center 018, Savannah
BC-3781 Study Center 012, Columbus
BC-3781 Study Center 004, Butte
BC-3781 Study Center 023, Lafayette
BC-3781 Study Center 021, Baton Rouge
BC-3781 Study Center 002, Chula Vista
BC-3781 Study Center 001, La Mesa
BC-3781 Study Center 003, Oceanside
BC-3781 Study Center 016, Somers Point
Lead Sponsor
Nabriva Therapeutics AG
INDUSTRY